These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 29673125)

  • 1. Major pathologic response and RAD51 predict survival in lung cancer patients receiving neoadjuvant chemotherapy.
    Pataer A; Shao R; Correa AM; Behrens C; Roth JA; Vaporciyan AA; Wistuba II; Swisher SG
    Cancer Med; 2018 Jun; 7(6):2405-2414. PubMed ID: 29673125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Agreement on Major Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemotherapy.
    Weissferdt A; Pataer A; Vaporciyan AA; Correa AM; Sepesi B; Moran CA; Wistuba II; Roth JA; Shewale JB; Heymach JV; Kalhor N; Cascone T; Hofstetter WL; Lee JJ; Swisher SG
    Clin Lung Cancer; 2020 Jul; 21(4):341-348. PubMed ID: 32279936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is major pathologic response sufficient to predict survival in resectable nonsmall-cell lung cancer patients receiving neoadjuvant chemotherapy?
    Cai JS; Li S; Yan SM; Yang J; Yang MZ; Xie CL; Li JB; Feng YF; Yang HX; Hou X
    Thorac Cancer; 2021 May; 12(9):1336-1346. PubMed ID: 33751832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Pathologic Response in Lymph Nodes of Patients With Lung Cancer Receiving Neoadjuvant Chemotherapy.
    Pataer A; Weissferdt A; Vaporciyan AA; Correa AM; Sepesi B; Wistuba II; Heymach JV; Cascone T; Swisher SG
    J Thorac Oncol; 2021 Aug; 16(8):1289-1297. PubMed ID: 33857666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathological response and tumor stroma immunogenic features predict long-term survival in non-small cell lung cancer after neoadjuvant chemotherapy.
    Wang S; Sun X; Dong J; Liu L; Zhao H; Li R; Yang Z; Cheng N; Wang Y; Fu L; Yi H; Lv Z; Huo H; Jin D; Mao Y; Yang L
    Cell Oncol (Dordr); 2024 Jun; 47(3):1005-1024. PubMed ID: 38319500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy.
    Pataer A; Kalhor N; Correa AM; Raso MG; Erasmus JJ; Kim ES; Behrens C; Lee JJ; Roth JA; Stewart DJ; Vaporciyan AA; Wistuba II; Swisher SG;
    J Thorac Oncol; 2012 May; 7(5):825-32. PubMed ID: 22481232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamics of peripheral blood inflammatory index predict tumor pathological response and survival among patients with locally advanced non-small cell lung cancer who underwent neoadjuvant immunochemotherapy: a multi-cohort retrospective study.
    Zhai W; Zhang C; Duan F; Xie J; Dai S; Lin Y; Yan Q; Rao B; Li L; Zhou Y; Zhao Z; Long H; Wang J
    Front Immunol; 2024; 15():1422717. PubMed ID: 39108262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maturation and abundance of tertiary lymphoid structures are associated with the efficacy of neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer.
    Sun X; Liu W; Sun L; Mo H; Feng Y; Wu X; Li C; Chen C; Li J; Xin Y; Zhang Z; Wang C; Zhang B; Yue D
    J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 37011953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non-small-cell lung cancer after neoadjuvant chemotherapy.
    William WN; Pataer A; Kalhor N; Correa AM; Rice DC; Wistuba II; Heymach J; Lee JJ; Kim ES; Munden R; Gold KA; Papadimitrakopoulou V; Swisher SG; Erasmus JJ;
    J Thorac Oncol; 2013 Feb; 8(2):222-8. PubMed ID: 23287849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of neoadjuvant immunochemotherapy and survival surrogate analysis of neoadjuvant treatment in IB-IIIB lung squamous cell carcinoma.
    Liu J; Zhu L; Tang M; Huang X; Gu C; He C; Lv X; Hu J
    Sci Rep; 2024 Mar; 14(1):5523. PubMed ID: 38448498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC.
    Hines JB; Cameron RB; Esposito A; Kim L; Porcu L; Nuccio A; Viscardi G; Ferrara R; Veronesi G; Forde PM; Taube J; Vokes E; Bestvina CM; Dolezal JM; Sacco M; Monteforte M; Cascone T; Garassino MC; Torri V
    J Thorac Oncol; 2024 Jul; 19(7):1108-1116. PubMed ID: 38461929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of EGFR driver mutations on pathologic regression in resectable locally advanced non-small cell lung cancer treated with neoadjuvant chemoradiation and completion surgery.
    Appel S; Bar J; Saad A; Marom EM; Urban D; Onn A; Gantz-Sorotsky H; Kremer RY; Ben-Nun A; Perelman M; Ofek E; Yacobi R; Daher S; Rasco A; Symon Z; Lawrence YR; Goldstein J
    Br J Radiol; 2023 Dec; 96(1152):20220763. PubMed ID: 37751214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial.
    Sun C; Liu Y; Zhang P; Wang X; Xu Y; Lin X; Ma X; Guo Y; Qiu S; Shao G; Yang Z; Ma K
    J Cancer Res Clin Oncol; 2023 Feb; 149(2):819-831. PubMed ID: 35192053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different pathological response and histological features following neoadjuvant chemotherapy or chemo-immunotherapy in resected non-small cell lung cancer.
    Alì G; Poma AM; Di Stefano I; Zirafa CC; Lenzini A; Martinelli G; Romano G; Chella A; Baldini E; Melfi F; Fontanini G
    Front Oncol; 2023; 13():1115156. PubMed ID: 36845706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. International Association for the Study of Lung Cancer Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant Therapy.
    Dacic S; Travis W; Redman M; Saqi A; Cooper WA; Borczuk A; Chung JH; Glass C; Lopez JM; Roden AC; Sholl L; Weissferdt A; Posadas J; Walker A; Zhu H; Wijeratne MT; Connolly C; Wynes M; Bota-Rabassedas N; Sanchez-Espiridion B; Lee JJ; Berezowska S; Chou TY; Kerr K; Nicholson A; Poleri C; Schalper KA; Tsao MS; Carbone DP; Ready N; Cascone T; Heymach J; Sepesi B; Shu C; Rizvi N; Sonett J; Altorki N; Provencio M; Bunn PA; Kris MG; Belani CP; Kelly K; Wistuba I;
    J Thorac Oncol; 2023 Oct; 18(10):1290-1302. PubMed ID: 37702631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of DNA repair RAD51 gene variants in overall survival of non-small cell lung cancer patients treated with first line chemotherapy.
    Nogueira A; Catarino R; Coelho A; Araújo A; Gomes M; Medeiros R
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):501-6. PubMed ID: 19960343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of driver mutation on the treatment outcome of early-stage lung cancer patients receiving neoadjuvant immunotherapy and chemotherapy.
    Su PL; Chen JY; Chu CY; Chen YL; Chen WL; Lin KY; Ho CL; Tsai JS; Yang SC; Chen CW; Wu YL; Tseng YL; Chang CC; Yen YT; Lin CY; Lin CC; Su WC
    Sci Rep; 2022 Feb; 12(1):3319. PubMed ID: 35228655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gefitinib as neoadjuvant therapy for resectable stage II-IIIA non-small cell lung cancer: A phase II study.
    Zhang Y; Fu F; Hu H; Wang S; Li Y; Hu H; Chen H
    J Thorac Cardiovasc Surg; 2021 Feb; 161(2):434-442.e2. PubMed ID: 32340810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Artificial Intelligence-Powered Assessment of Pathologic Response to Neoadjuvant Atezolizumab in Patients With NSCLC: Results From the LCMC3 Study.
    Dacic S; Travis WD; Giltnane JM; Kos F; Abel J; Hilz S; Fujimoto J; Sholl L; Ritter J; Khalil F; Liu Y; Taylor-Weiner A; Resnick M; Yu H; Hirsch FR; Bunn PA; Carbone DP; Rusch V; Kwiatkowski DJ; Johnson BE; Lee JM; Hennek SR; Wapinski I; Nicholas A; Johnson A; Schulze K; Kris MG; Wistuba II
    J Thorac Oncol; 2024 May; 19(5):719-731. PubMed ID: 38070597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survivin mRNA Level in Blood Predict the Efficacy of Neoadjuvant Chemotherapy in Patients with Stage IIIA-N2 Non-Small Cell Lung Cancer.
    Hu YM; Li J; Yu LC; Shi SB; Du YJ; Wu JN; Shi WL
    Pathol Oncol Res; 2015 Apr; 21(2):257-65. PubMed ID: 24980156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.